Several tumor-related factors have been shown to influence response to immune therapies, including the tumor mutational burden (TMB) and neoantigen load [60], or the mutation in genes that influence tumor ability to escape immune surveillance [56] (e.g., MYC or RAS [61,62]) or respond to interferon-gamma (IFNγ) signaling [63]. Here, MYC is linked to neoplasm.